Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | MLYCD | O95822 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 3/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 4/20 | 0.32 |
| ▸ | CA1 | P00915 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | TERT | O14746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7991659 | 0.92 | MLYCD (0.39) | RECQLMLYCDMAOAMAOBEPHX2 | |
| SCHEMBL13292141 | 0.88 | RECQL (0.38) | RECQLMAOAMAOBGAATDP1 | |
| SCHEMBL6575441 | 0.88 | RECQL (0.38) | RECQLMAOAMAOBGAATDP1 | |
| Hydrochloric Acid SCHEMBL9087860 | 0.86 | RECQL (0.37) | RECQLMAOAMAOBGAATDP1 | |
| SCHEMBL16006902 | 0.85 | RECQL (0.38) | RECQLMLYCDMAOAMAOBEPHX2 | |
| SCHEMBL2558596 | 0.84 | RECQL (0.41) | RECQLMAOAMAOBGAATDP1 | |
| SCHEMBL23482834 | 0.83 | EPHX2 (0.45) | RECQLMAOAMAOBEPHX2GAA | |
| SCHEMBL17570955 | 0.83 | LMNA (0.46) | RECQLEPHX2GAACA2KDM4E | |
| SCHEMBL18913048 | 0.83 | LMNA (0.46) | RECQLEPHX2GAACA2KDM4E | |
| Hydrochloric Acid SCHEMBL715683 | 0.83 | RECQL (0.39) | RECQLMAOAMAOBGAATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11505617-B2 | Benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2022-11-22 | — | — | US | disclosed |
| US-20210238301-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2021-08-05 | — | — | US | disclosed |
| US-11046762-B2 | Cross-linkers and their uses | IMMUNOGEN, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-11046762-B2 | Cross-linkers and their uses | IMMUNOGEN, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-10947315-B2 | Benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| US-20200148764-A1 | CROSS-LINKERS AND THEIR USES | IMMUNOGEN, INC. | 2020-05-14 | — | — | US | disclosed |
| US-20200148764-A1 | CROSS-LINKERS AND THEIR USES | IMMUNOGEN, INC. | 2020-05-14 | — | — | US | disclosed |
| US-20190276552-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2019-09-12 | — | — | US | disclosed |
| US-10208127-B2 | Benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-10208127-B2 | Benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| EP-2281006-A1 | CROSS-LINKERS AND THEIR USES | Immunogen, Inc. (US) | 2011-02-09 | — | — | EP | disclosed |
| US-20100203007-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | IMMUNOGEN INC. (US) | 2010-08-12 | — | — | US | disclosed |
| US-20100203007-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | IMMUNOGEN INC. (US) | 2010-08-12 | — | — | US | disclosed |
| US-20100203007-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | IMMUNOGEN INC. (US) | 2010-08-12 | — | — | US | disclosed |
| WO-2010091150-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. (US) | 2010-08-12 | — | — | WO | disclosed |
| US-20090274713-A1 | CROSS-LINKERS AND THEIR USES | IMMUNOGEN INC. (US) | 2009-11-05 | — | — | US | disclosed |
| US-20090274713-A1 | CROSS-LINKERS AND THEIR USES | IMMUNOGEN INC. (US) | 2009-11-05 | — | — | US | disclosed |
| US-20090274713-A1 | CROSS-LINKERS AND THEIR USES | IMMUNOGEN INC. (US) | 2009-11-05 | — | — | US | disclosed |
| WO-2009134977-A1 | CROSS-LINKERS AND THEIR USES | IMMUNOGEN, INC. (US) | 2009-11-05 | — | — | WO | disclosed |
| WO-2009134977-A1 | CROSS-LINKERS AND THEIR USES | IMMUNOGEN, INC. (US) | 2009-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238301-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | GABRB1, GABRB3, GABRA1 | RECQL 3865/4885MLYCD 2429/4885MAOA 1164/4885 |
| US-20090274713-A1 | CROSS-LINKERS AND THEIR USES | MTCL3, DCLRE1A, PCNA | RECQL 3353/4885MLYCD 4713/4885MAOA 3447/4885 |
| US-10208127-B2 | Benzodiazepine derivatives | GABBR1, GABRB1, GABRA1 | RECQL 3469/4885MLYCD 2305/4885MAOA 874/4885 |
| US-20190276552-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | GABRB1, GABRB3, GABRA1 | RECQL 3865/4885MLYCD 2429/4885MAOA 1164/4885 |
| US-20200148764-A1 | CROSS-LINKERS AND THEIR USES | MTCL3, DCLRE1A, PCNA | RECQL 3353/4885MLYCD 4713/4885MAOA 3447/4885 |
| US-20100203007-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | GABRB1, GABRB3, GABRA1 | RECQL 3865/4885MLYCD 2429/4885MAOA 1164/4885 |
| US-11505617-B2 | Benzodiazepine derivatives | GABBR1, GABRB1, GABRA1 | RECQL 3469/4885MLYCD 2305/4885MAOA 874/4885 |
| US-10947315-B2 | Benzodiazepine derivatives | GABBR1, GABRB1, GABRA1 | RECQL 3469/4885MLYCD 2305/4885MAOA 874/4885 |
| US-11046762-B2 | Cross-linkers and their uses | MTCL3, DCLRE1A, PCNA | RECQL 3353/4885MLYCD 4713/4885MAOA 3447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.